CAJ | 학술논문

目的:拟评价铜绿假单胞菌注射液(PA-MSHA菌苗)联合新辅助化疗治疗乳腺癌的有效性和安全性.方法:本研究为开旅、随机、对照试验.试验组乳腺癌患者20例,对照组20例,两组采用相同的化疗方案,试验组加用铜绿假单胞菌注射液.治疗结束后评价疗效,记录患者治疗前、后的Karnofsky评分,并在治疗前、后抽取患者静脉血,采用双抗体夹心ELISA法检测患者的免疫功能指标(IFN-γ、IL-2、IL-4、IL-10)和其他指标(Caspase-3、VEGF、MMP-2、MMP-9)的变化情况,观察并记录不良反应.结果:治疗后试验组的总缓解率(RR)高于对照组(P<0.05),试验组的术后病理完全缓解率(pCR)高于对照组,但差异无统计学意义(P>0.05);试验组治疗前和治疗后Karnofsky评分比较,差异有统计学意义(P<0.01),试验组治疗后Karnofsky评分显著高于对照组治疗后(P<0.01);试验组治疗后血清IFN-γ和IL-2水平高于对照组(P<0.01),IL-4和IL-10水平低于对照组(P<0.05);试验组治疗后血清Caspase-3浓度升高,VEGF、MMP-2和MMP-9血清浓度降低,治疗前、后比较差异有统计学意义(P<0.05);对照组MMP-9与治疗前相比显著降低(P<0.01).结论:铜绿假单胞菌注射液与化疗药物联合应用治疗乳腺癌可以提高总缓解率,能明显改善乳腺癌患者的细胞免疫功能,同时诱导乳腺癌细胞凋亡,降低乳腺癌细胞的侵袭能力,是乳腺癌患者理想的辅助治疗药物.
목적:의평개동록가단포균주사액(PA-MSHA균묘)연합신보조화료치료유선암적유효성화안전성.방법:본연구위개려、수궤、대조시험.시험조유선암환자20례,대조조20례,량조채용상동적화료방안,시험조가용동록가단포균주사액.치료결속후평개료효,기록환자치료전、후적Karnofsky평분,병재치료전、후추취환자정맥혈,채용쌍항체협심ELISA법검측환자적면역공능지표(IFN-γ、IL-2、IL-4、IL-10)화기타지표(Caspase-3、VEGF、MMP-2、MMP-9)적변화정황,관찰병기록불량반응.결과:치료후시험조적총완해솔(RR)고우대조조(P<0.05),시험조적술후병리완전완해솔(pCR)고우대조조,단차이무통계학의의(P>0.05);시험조치료전화치료후Karnofsky평분비교,차이유통계학의의(P<0.01),시험조치료후Karnofsky평분현저고우대조조치료후(P<0.01);시험조치료후혈청IFN-γ화IL-2수평고우대조조(P<0.01),IL-4화IL-10수평저우대조조(P<0.05);시험조치료후혈청Caspase-3농도승고,VEGF、MMP-2화MMP-9혈청농도강저,치료전、후비교차이유통계학의의(P<0.05);대조조MMP-9여치료전상비현저강저(P<0.01).결론:동록가단포균주사액여화료약물연합응용치료유선암가이제고총완해솔,능명현개선유선암환자적세포면역공능,동시유도유선암세포조망,강저유선암세포적침습능력,시유선암환자이상적보조치료약물.
Objective: To evaluate the effect and safety of neoadjuvant chemotherapy combined with PA-MSHA injection for breast cancer patients. Methods: An open randomized controlled clinical trial was con-ducted. Fourty patients with breast cancer were randomly assigned to neoadjuvant chemotherapy group (the control group, n=20) and neoadjuvant chemotherapy combined with PA-MSHA injection group (the experi-ment group, n=20). The evaluation of therapeutic effect was carried out when the treatment was completed. Kamofsky score was recorded before and after therapy. Venous blood was drawn before and after therapy and immune function (IFN-γ, IL-2, IL-4, and IL-10) and other indicators (Caspase-3, VEGF, MMP-2 and MMP-9) were measured by double antibody ELISA test. Adverse effects of PA-MSHA during therapy were ob-served and recorded. Results: The overall response rate (RR) in the experiment group was significantly higher than that in the control group (P<0.05). No significant difference was found in the pathologic complete remis-sion (pCR) between the experiment group and the control group (P>0.05). In the experimental group, pCR was significantly different before and after therapy (P<0.01). The score in the experimental group was signifi-cantly higher than that in the control group after therapy (P<0.01). With the treatment of chemotherapy and PA-MSHA injection, IFN-γ and IL-2 levels were significantly higher while IL-4 and IL-10 levels were significant-ly lower in the experiment group (P<0.05). A significant increase in serum Caspase-3 and a significant de-crease in serum VEGF, MMP-2 and MMP-9 (P<0.05) after therapy were also observed in the experimental group. The level of serum MMP-9 was decreased significantly (P=<0.05) after therapy in the control group. Con-clusion: Neoadjuvant chemotherapy combined with PA-MSHA injection can significantly improve the RR of breast cancer patients, enhance their cellular immune function, induce the apoptosis and restrain the metasta-sis of breast cancer cells. The PA-MSHA has been proved to be an ideal supplementary therapy for breast cancer.